Literature DB >> 3079288

Mechanisms and clinical significance of multidrug resistance.

C S Morrow1, K H Cowan.   

Abstract

Tumor cells often become refractory to diverse drugs with different mechanisms of cytotoxic action. This paper reviews the current state of our knowledge of multidrug resistance, the limitations of present concepts to fully explain the diversity of the MDR phenotypes, and the clinical relevance of these studies derived largely from cell culture systems. The authors discuss the use of markers associated with the multi-drug resistance phenotype to identify potentially drug-resistant tumors and outline strategies that might be used to overcome the resistance phenomenon.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3079288

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  17 in total

1.  Drug resistance in cancer therapy.

Authors:  Vinod Labhasetwar
Journal:  Drug Deliv Transl Res       Date:  2011-12       Impact factor: 4.617

2.  Influences of "spasmolytic powder" on pgp expression of Coriaria Lactone-kindling drug-resistant epileptic rat model.

Authors:  Lei Chen; Peimin Feng; Yaohua Li; Dong Zhou
Journal:  J Mol Neurosci       Date:  2012-12-20       Impact factor: 3.444

3.  Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.

Authors:  S Oudard; A Thierry; T J Jorgensen; A Rahman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.

Authors:  T W Beer; D C Rowlands; J Crocker
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

5.  Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant.

Authors:  R R Perry; B R Greaves; Y Kang
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Inhibition of P-glycoprotein over-expression by shRNA-mdr1b in rat astrocytes.

Authors:  Lei Chen; Xinwang Cheng; Linyu Tian; Tianhua Yang; Stefan Hermann; Dong Zhou
Journal:  Neurochem Res       Date:  2008-08-02       Impact factor: 3.996

Review 7.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

8.  MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.

Authors:  C Ramachandran; A Sauerteig; K S Sridhar; R J Thurer; A Krishan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

Authors:  S de Jong; J G Zijlstra; N H Mulder; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Reversal of mdr1b-dependent multidrug resistance in a rat astrocyte model by adenoviral-delivered short hairpin RNA.

Authors:  Lei Chen; Linyu Tian; Tianhua Yang; Xinwang Cheng; Stefan Hermann; Dong Zhou
Journal:  Cell Mol Neurobiol       Date:  2008-04-25       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.